{
    "root": "3aec3da3-a8fc-4996-b2e2-3d4f029e35cf",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Carbidopa, Levodopa, and Entacapone",
    "value": "20231130",
    "ingredients": [
        {
            "name": "CARBIDOPA",
            "code": "MNX7R8C5VO",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_3395"
        },
        {
            "name": "LEVODOPA",
            "code": "46627O600J",
            "drugbank_id": "https://go.drugbank.com/drugs/DB01235"
        },
        {
            "name": "ENTACAPONE",
            "code": "4975G9NM6T",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_4798"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "GLYCERIN",
            "code": "PDC6A3C0OX",
            "drugbank_id": "https://go.drugbank.com/drugs/DB09462"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_29864"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_53426"
        },
        {
            "name": "POVIDONE, UNSPECIFIED",
            "code": "FZ989GH94E"
        },
        {
            "name": "SUCROSE",
            "code": "C151H8M554",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17992"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        }
    ],
    "indications": {
        "text": "carbidopa , levodopa entacapone tablets indicated treatment parkinson 's disease . carbidopa , levodopa entacapone tablets used : \u2022to substitute ( equivalent strengths three components ) carbidopa/levodopa entacapone previously administered individual products . \u2022to replace carbidopa/levodopa therapy ( without entacapone ) patients experience signs symptoms end-of-dose \u201c wearing-off \u201d taking total daily dose levodopa 600 mg less experiencing dyskinesias .",
        "doid_entities": [
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "carbidopa , levodopa entacapone tablets used substitute patients already stabilized equivalent doses carbidopa/levodopa entacapone . however , patients stabilized given dose carbidopa/levodopa may treated carbidopa , levodopa entacapone tablets decision made add entacapone ( ) . therapy individualized adjusted according desired therapeutic response .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "carbidopa , levodopa entacapone tablets supplied film-coated tablets oral following six strengths : carbidopa , levodopa entacapone film-coated tablets containing 12.5 mg carbidopa , 50 mg levodopa , 200 mg entacapone . round , bi-convex shaped tablets brownish- greyish-red , unscored , embossed \u201c lce 50 \u201d one side . ndc 0781-5613-01 hdpe bottle 100 tablets carbidopa , levodopa entacapone film-coated tablets containing 18.75 mg carbidopa , 75 mg levodopa , 200 mg entacapone . oval-shaped tablets light brownish red , unscored embossed code \u201c lce 75 \u201d one side . ndc 0781-5625-01 hdpe bottle 100 tablets carbidopa , levodopa entacapone film-coated tablets containing 25 mg carbidopa , 100 mg levodopa , 200 mg entacapone . oval-shaped tablets brownish- greyish-red , unscored , embossed \u201c lce 100 \u201d one side . ndc 0781-5637-01 hdpe bottle 100 tablets carbidopa , levodopa entacapone film-coated tablets containing 31.25 mg carbidopa , 125 mg levodopa , 200 mg entacapone . oval-shaped tablets light brownish red , unscored embossed code \u201c lce 125 \u201d one side . ndc 0781-5641-01 hdpe bottle 100 tablets carbidopa , levodopa entacapone film-coated tablets containing 37.5 mg carbidopa , 150 mg levodopa , 200 mg entacapone . elongated-ellipse shaped tablets brownish- greyish-red , unscored , embossed \u201c lce 150 \u201d one side . ndc 0781-5654-01 hdpe bottle 100 tablets carbidopa , levodopa entacapone film-coated tablets containing 50 mg carbidopa , 200 mg levodopa , 200 mg entacapone . oval shaped tablets dark brownish red , unscored , embossed \u201c lce 200 \u201d one side . ndc 0781-5669-01 hdpe bottle 100 tablets",
    "adverseReactions": "carbidopa , levodopa entacapone tablets contraindicated patients : \u2022taking nonselective monoamine oxidase ( mao ) inhibitors ( e.g . , phenelzine tranylcypromine ) . nonselective mao inhibitors must discontinued least two weeks prior initiating therapy carbidopa , levodopa entacapone tablets . \u2022with narrow-angle glaucoma .",
    "indications_original": "Carbidopa, levodopa and entacapone tablets are indicated for the treatment of Parkinson's disease.\n                  Carbidopa, levodopa and entacapone tablets can be used:\n                  \n                     \n                        \u2022To substitute (with equivalent strengths of each of the three components) carbidopa/levodopa and entacapone previously administered as individual products.\n                     \n                        \u2022To replace carbidopa/levodopa therapy (without entacapone) when patients experience the signs and symptoms of end-of-dose \u201cwearing-off\u201d and when they have been taking a total daily dose of levodopa of 600\u00a0mg or less and have not been experiencing dyskinesias.",
    "contraindications_original": "Carbidopa, levodopa and entacapone tablets should be used as a substitute for patients already stabilized on equivalent doses of carbidopa/levodopa and entacapone. However, some patients who have been stabilized on a given dose of carbidopa/levodopa may be treated with carbidopa, levodopa and entacapone tablets if a decision has been made to add entacapone (see below). Therapy should be individualized and adjusted according to the desired therapeutic response.",
    "warningsAndPrecautions_original": "Carbidopa, levodopa and entacapone tablets are supplied as film-coated tablets for oral administration in the following six strengths:\n                  Carbidopa, levodopa and entacapone film-coated tablets containing 12.5\u00a0mg of carbidopa, 50\u00a0mg of levodopa, and 200\u00a0mg of entacapone.\n                  The round, bi-convex shaped tablets are brownish- or greyish-red, unscored, and embossed \u201cLCE 50\u201d on one side.\n                  \n                     \n                        \u00a0NDC 0781-5613-01 HDPE bottle of 100\u00a0tablets\n                  \n                  Carbidopa, levodopa and entacapone film-coated tablets containing 18.75\u00a0mg of carbidopa, 75\u00a0mg of levodopa, and 200\u00a0mg of entacapone.\n                  The oval-shaped tablets are light brownish red, unscored and embossed with code \u201cLCE 75\u201d on one side.\n                  \n                     \n                        \u00a0NDC 0781-5625-01 HDPE bottle of 100\u00a0tablets\n                  \n                  Carbidopa, levodopa and entacapone film-coated tablets containing 25\u00a0mg of carbidopa, 100\u00a0mg of levodopa, and 200\u00a0mg of entacapone.\n                  The oval-shaped tablets are brownish- or greyish-red, unscored, and embossed \u201cLCE 100\u201d on one side.\n                  \n                     \n                        \u00a0NDC 0781-5637-01 HDPE bottle of 100\u00a0tablets\n                  \n                  Carbidopa, levodopa and entacapone film-coated tablets containing 31.25\u00a0mg of carbidopa, 125\u00a0mg of levodopa, and 200\u00a0mg of entacapone.\n                  The oval-shaped tablets are light brownish red, unscored and embossed with code \u201cLCE 125\u201d on one side.\n                  \n                     \n                        \u00a0NDC 0781-5641-01 HDPE bottle of 100\u00a0tablets\n                  \n                  Carbidopa, levodopa and entacapone film-coated tablets containing 37.5\u00a0mg of carbidopa, 150\u00a0mg of levodopa, and 200\u00a0mg of entacapone.\n                  The elongated-ellipse shaped tablets are brownish- or greyish-red, unscored, and embossed \u201cLCE 150\u201d on one side.\n                  \n                     \n                        \u00a0NDC 0781-5654-01 HDPE bottle of 100\u00a0tablets\n                  \n                  Carbidopa, levodopa and entacapone film-coated tablets containing 50\u00a0mg of carbidopa, 200\u00a0mg of levodopa, and 200\u00a0mg of entacapone.\n                  The oval shaped tablets are dark brownish red, unscored, and embossed \u201cLCE 200\u201d on one side.\n                  \n                     \n                        \u00a0NDC 0781-5669-01 HDPE bottle of 100\u00a0tablets",
    "adverseReactions_original": "Carbidopa, levodopa and entacapone tablets are contraindicated in patients:\n                  \n                     \n                        \u2022Taking nonselective monoamine oxidase (MAO) inhibitors (e.g., phenelzine and tranylcypromine). These nonselective MAO inhibitors must be discontinued at least two weeks prior to initiating therapy with carbidopa, levodopa and entacapone tablets.\n                     \n                        \u2022With narrow-angle glaucoma.",
    "drug": [
        {
            "name": "Carbidopa, Levodopa, and Entacapone",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_3395"
        }
    ]
}